Pint Pharma

Pint Pharma is a privately held specialty pharmaceutical company with professional leaders who have extensive experience in the pharmaceutical field. The company has strategic bases across Latin America and Europe. Pint Pharma also has a long-standing track record of building strong relationships with global pharmaceutical and healthcare companies. Pint Pharma aims to become a leading Latin American company providing innovative therapies for patients with cancer, rare diseases, and genetic disorders. Recently, Pint Pharma announced the approval of ORLADEYO® (berotralstat), the first oral therapy in Brazil for the prevention of hereditary angioedema (HAE) attacks in Brazilian adults and children aged 12 years and older.